Sign in Subscribe
Banking industry

Transkaryotic Therapies, Inc. to Present at Deutsche Bank Securities 29th Annual Healthcare Conference

Strategic Insights

— 1 min read

Transkaryotic Therapies, Inc. is a biopharmaceutical company focused on researching and developing treatments for rare diseases caused by protein deficiencies. The company will participate in the Deutsche Bank Securities 29th Annual Healthcare Conference, presenting an overview of its business activities. This event will be an opportunity for investors and stakeholders to learn more about the company's advancements and goals in the field of rare diseases.

Key Takeaways:

  • Transkaryotic Therapies, Inc. will present at the Deutsche Bank Securities 29th Annual Healthcare Conference in Baltimore, Maryland, on May 5, 2004.
  • The presentation will be given by Michael J. Astrue, President and Chief Executive Officer, at 9:30 a.m. Eastern Time.
  • A live audio webcast of the presentation will be available on TKT's Investor Information website, accessible through http://www.tktx.com/.
  • A replay of the presentation will be available until May 19, 2004.
  • The company's main focus is on researching and developing treatments for rare diseases caused by protein deficiencies, including Fabry disease, Hunter syndrome, and Gaucher disease.
  • TKT is also developing a product for anemia related to kidney disease, Dynepo(TM), which will be commercialized in the European Union.
  • The company was founded in 1988 and is headquartered in Cambridge, Massachusetts, with additional operations in Europe, Canada, and Latin America.
  • Gene-Activated(R) is a registered trademark and Replagal(TM) is a trademark of Transkaryotic Therapies, Inc., while Dynepo(TM) is a trademark of Aventis Pharmaceuticals, Inc.

Statistics:

  • Date of the presentation: Wednesday, May 5, 2004
  • Time of presentation: 9:30 a.m. Eastern Time
  • Availability of live audio webcast: through http://www.tktx.com/ on the Investor Information website under the Events category
  • Availability of replay: until May 19, 2004

Sources:

  • [Transkaryotic Therapies, Inc. press release, May 4, 2004]
  • [Company's website: http://www.tktx.com/]
  • [Deutsche Bank Securities 29th Annual Healthcare Conference]
  • [Aventis Pharmaceuticals, Inc.]

Read more